Format

Send to

Choose Destination
Mol Med Rep. 2018 Mar;17(3):4540-4546. doi: 10.3892/mmr.2018.8458. Epub 2018 Jan 18.

The roles of TRIO and F-actin-binding protein in glioblastoma cells.

Author information

1
Department of Pharmacology and Medical Science, Metabolic Syndrome and Cell Signaling Laboratory, Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Daejeon, Chungcheongnam‑do 35015, Republic of Korea.
2
Laboratory of Cancer Cell Biology, Department of Biochemistry, School of Medicine, Gachon University, Incheon, Gyeonggi‑do 21999, Republic of Korea.
3
Centre for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK.
4
Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, Chungcheongnam‑do 35015, Republic of Korea.

Abstract

TRIO and F-actin-binding protein (TrioBP), which was initially discovered as a binding partner of Trio and F‑actin, is a critical factor associated with hearing loss in humans. However, the function of TrioBP in cancer has not been investigated. In the present study, TrioBP expression was indicated to be highly elevated in U87‑MG and U343‑MG cells. Furthermore, the TrioBP mRNA expression level was markedly increased in U87‑MG and U251‑MG cells compared with that in cerebral cortex cells, as determined by deep sequencing. Comprehensive analysis of a public TCGA dataset confirmed that TrioBP expression is elevated in patients with glioblastoma. In summary, the present data indicate that TrioBP expression is increased in glioblastoma cell lines and in patients with glioma, suggesting that TrioBP has potential as a diagnostic marker or therapeutic agent for glioma.

PMID:
29363730
PMCID:
PMC5802229
DOI:
10.3892/mmr.2018.8458
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Spandidos Publications Icon for PubMed Central
Loading ...
Support Center